West Pharmaceutical Services management check

WST · Health Care · Health Care Supplies · CEO Eric M. Green

Filings as of

63
Management score, ranked 281st of 487 · 32nd of 60 in Health Care3 good · 2 to watch · 1 flaggedStrongest: clean books · Weakest: owner returns · Best and worst run in Health Care →

The seven checks

  • Flag

    Have owners done well?

    Trailed its chosen peersOwners$59Peers$118

    What $100 became since fiscal 2021

    016th
    Detail

    $100 invested at the start of fiscal 2021 grew to $59, against $118 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20212025

    Pay actually paid $100 value, each on its own scale

    9995th
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.97 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Watch

    What does the CEO cost owners?

    1.5% of net income

    $7.2m pay · $494.0m net income, FY2025

    0.1%1%3%10%
    3638th
    Detail

    $7.2m of reported pay in fiscal 2025, against $494.0m of net income.

  • n/a

    Do they own the stock?

    No recent CEO filing
    ——

    Light activity: no buys, $5.4m sold in six months. 3 of 6 sales ran on pre-arranged 10b5-1 plans.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 76m2025 · 73m

    Diluted shares −1.7% a year; flagged above +2%

    0%10%20%

    Stock pay 0.8% of revenue

    7264th
    Detail

    Diluted shares changed -1.7% a year over the last three fiscal years. Stock-based pay was 0.8% of revenue in the latest year.

  • Watch

    Is leadership stable?

    11 leadership filings in 3 years

    11 filings under 8-K 5.02 in 3 years

    0101420+

    CEO: Eric M. Green

    7046th
    Detail

    CEO in the pay table: Eric M. Green. 11 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed March 12, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
−$12.1m$11.5m$35.1m$10020212022202320242025$59$118

Pay tied most to Revenue

Other key measuresEarnings per ShareOperating Cash FlowConsolidated Gross ProfitSales Compounded Annual Growth RateReturn on Invested Capital

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Eric M. Green$7.2m$4.1m$3.8m$59$118$494.0m
2024—$8.4m$5.3m$1.8m$70$103$493.0m
2023—$9.4m$17.0m$2.1m$75$100$593.0m
2022—$7.9m−$12.1m$1.8m$50$98$586.0m
2021—$9.5m$35.1m$2.0m$100$100$662.0m

Insiders and the CEO's stakeQuiet

Light activity: no buys, $5.4m sold in six months. 3 of 6 sales ran on pre-arranged 10b5-1 plans.

Open-market trades by officers and directors since May 21, 2026.

  • SoldAnnette F FavoriteSr. VP & Chief HR Officer$5.4mSep 15, 2026

Leadership and governance on file

20222023202420252026Leadership 14Votes 6
All 14 filings

Latest shareholder vote results: May 5, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $1.8bn returned to owners in buybacks and dividends, 62% of net income, and $127.0m of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$330.9m$661.8m20212022202320242025Shares76m76m75m74m73m
Show the figures
Fiscal year20212022202320242025
Revenue$2.8bn$2.9bn$2.9bn$2.9bn$3.1bn
Net income$661.8m$585.9m$593.4m$492.7m$493.7m
Stock-based pay$37.5m$23.7m$23.3m$18.7m$23.8m
Buybacks$137.1m$202.8m$438.3m$560.9m$134.0m
Dividends$51.1m$54.1m$57.0m$59.1m$61.2m
Diluted shares76m76m75m74m73m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.